Process development excellence to de-risk and accelerate commercialization of cell and gene therapies
Sponsor
In order to commercialize cell and gene therapies and treat large number of patients, it is important to demonstrate the safety and efficacy of these therapies and establish robust and reliable manufacturing processes. Here, we introduce some of the bioprocessing best practices applied in early development phase to de-risk manufacturing and develop commercially viable cell and gene therapies.
Following a carefully planned manufacturability assessment, appropriate development studies must be designed to implement innovative technologies with appropriate in process control and analytical monitoring methods to ensure robustness and reproducibility of the manufacturing process. It is also important to eliminate open and variable manual unit operations whilst incorporating comprehensive characterization assays in the process to verify long-term stability of the products. The development of automated, scalable, computer-controlled 3D bioreactors with appropriate downstream and cell processing technologies may be critical to minimize GMP manufacturing risks and produce high quality cell therapy products.
SPEAKERS
You might also like
Accelerate the scale-up to clinical phase: optimizing stem cell culture performance and viral vector titers
Think ahead: preparing for challenges to accelerate your cell therapy commercialization
Optimizing access to high quality, standardized, and compliant leukopaks for the development and commercialization of allogeneic therapies
Overcoming the limits of lentivirus: de-risk cell therapy development with non-viral genome engineering
